SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Consensus Development Conference 1993 Diagnosis, prophylaxis and treatment of osteoporosis. Am J Med 94: 646650.
  • 2
    World Health Organization. Assessment of Fracture Risk and Its Application to Screening for Postmenopausal Osteoporosis. World Health Organization, Geneva, Switzerland, 1129.
  • 3
    Jordan KM, Cooper C 2002 Epidemiology of osteoporosis. Best Pract Res Clin Rheumatol 16: 795806.
  • 4
    Siris ES, Chen YT, Abbott TA, Barrett-Connor E, Miller PD, Wehren LE, Berger ML 2004 Bone mineral density thresholds for pharmacological intervention to prevent fractures. Arch Intern Med 164: 11081112.
  • 5
    Sanders KM, Nicholson GC, Watts JJ, Pasco JA, Henry MJ, Kotowicz MA, Seeman E 2006 Half the burden of fragility fractures in the community occur in women without osteoporosis. When is fracture prevention cost effective? Bone 38: 694700.
  • 6
    Delmas PDD 2002 Treatment of postmenopausal osteoporosis. Lancet 359: 20182026.
  • 7
    Simon JA 2005 Does osteopenia warrant treatment? Menopause 12: 639648.
  • 8
    Meunier PJ, Roux C, Seeman E, Ortolani S, Badurski JE, Spector TD, Cannata J, Balogh A, Lemmel EM, Pors-Nielsen S, Rizzoli R, Genant HK, Reginster JY 2004 The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med 350: 459468.
  • 9
    Reginster JY, Seeman E, De Vernejoul MC, Adami S, Compston J, Phenekos C, Devogelaer JP, Curiel MD, Sawicki A, Goemaere S, Sorensen OH, Felsenberg D, Meunier PJ 2005 Strontium ranelate reduces the risk of non vertebral fractures in postmenopausal women with osteoporosis: TReatment Of Peripheral OSsteoporosis (TROPOS) Study. J Clin Endocrinol Metab 90: 28162822.
  • 10
    Genant HK, Wu CY, Van Kuijk C, Nevitt MC 1993 Vertebral fracture assessment using a semiquantitative technique. J Bone Miner Res 8: 11371148.
  • 11
    Slosman D, Provvedini DM, Meunier PJ, Delmas PD, Sebert JL, De Vernejoul MC, Tsouderos Y, Reginster JY 1999 The use of different dual X-ray absorptiometry brands in a multicenter clinical trial. J Clin Densitom 2: 3744.
  • 12
    Kanis JA, Johnell O, Black DM, Downs RW, Sarkar S, Fuerst T, Secrest RJ, Pavo I 2003 Effect of raloxifene on the risk of new vertebral fracture in postmenopausal women with osteopenia or osteoporosis: A reanalysis of the Multiple Outcomes of Raloxifene Evaluation Trial. Bone 33: 293300.
  • 13
    Quandt SA, Thomspon DE, Schneider DL, Nevitt MC, Black DM 2005 Fracture intervention Trial Research Group. Effect of alendronate on vertebral fracture risk in women with bone mineral density T scores of −1.6 to −2.5 at the femoral neck: The Fracture Intervention Trial. Mayo Clin Proc 80: 343349.
  • 14
    Heaney RP, Zizic TM, Fogelman I, Oszynski WP, Geusens P, Kasibhatla C, Alsayed N, Isaia G, Davie MW, Chesnut CH 2002 Risedronate reduces the risk of first vertebral fracture in osteoporotic women. Osteoporos Int 13: 501505.
  • 15
    Sornay-Rendu E, Munoz F, Garnero P, Duboeuf F, Delmas PD 2005 Identification of osteopenic women at high risk of fracture: The OFELY Study. J Bone Miner Res 20: 18131819.
  • 16
    Garnero P, Delmas PD 2004 Contribution of bone mineral density and bone turnover markers to the estimation of risk of osteoporotic fracture in postmenopausal women. J Musculoskel Neuron Interact 4: 5063.